[{"id":"463587d3-e808-4685-9d40-3926117c11c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06654050","created_at":"2025-02-25T12:31:09.116Z","updated_at":"2025-02-25T12:31:09.116Z","phase":"Phase 2","brief_title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","source_id_and_acronym":"NCT06654050","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":"","alterations":" ","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alrizomadlin (APG-115)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-24"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"0a3b1baf-6e1d-473c-832a-6e95be260fa7","acronym":"APG-115-US-001","url":"https://clinicaltrials.gov/study/NCT02935907","created_at":"2021-01-18T14:25:00.156Z","updated_at":"2024-07-02T16:36:07.447Z","phase":"Phase 1","brief_title":"APG-115 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02935907 - APG-115-US-001","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alrizomadlin (APG-115)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2022-07-12"}]